Why Vertex Pharmaceuticals Stock Topped the Market Today
The big biotech might just have a winner on its hands with an investigational pain treatment. VX-548 performed well in late-stage clinical testing, although there were some caveats.
Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain
The trial results bring the biotech company one step closer to developing a drug that can provide strong pain relief without the addictive potential of opioids.
Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here's Why
Vertex Pharmaceuticals (VRTX) closed at $435.82 in the latest trading session, marking a +1.31% move from the prior day.
Here's My Top Growth Stock to Buy Right Now
This stock is already highly profitable with a huge cash stockpile thanks to a monopoly in its core niche market. It offers tremendous growth potential with multiple near-term catalysts.
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals' work in cystic fibrosis isn't done yet. The company also stands to make headway in other areas over time.
Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) an...
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
Vertex Pharmaceuticals (VRTX) reachead $439.70 at the closing of the latest trading day, reflecting a -0.09% change compared to its last close.
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
CRISPR-derived drug gets green light for second indication
The Food & Drug Administration has approved a second indication for a drug developed using a gene editing process called CRISPR. Casgevy, initially authorised in December for sickle cell disease tr...
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $421.01, indicating a +0.45% shift from the previous trading day.
Vertex Pharmaceuticals Incorporated (VRTX) J.P. Morgan 42nd Annual Healthcare Conference
Vertex Pharmaceuticals Incorporated (VRTX) J.P. Morgan 42nd Annual Healthcare Conference
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $409.27, indicating a +0.3% shift from the previous trading day.
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex has a lock on the market for cystic fibrosis (CF) medicines. Now, it's also commercializing a promising, new gene therapy.
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 42nd Annual J.P. ...
Related Companies